ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interleukin 1 Receptor Antagonist Protein

Also written as “Anakinra”, “Anakinra (Kineret®)” and “anakinra”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Familial Mediterranean Fever · COVID-19 · Still's Disease, Adult-Onset, led by 3 companies.

Drug pageInterleukin 1 Receptor Antagonist Protein: every studyAll 168 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 20, 200514 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only70 open or runningphase 4since May 20, 2005May 17, 2002none ahead
Swedish Orphan Biovitrum61 open or runningphase 4since Oct 8, 2024Dec 13, 2016none ahead
Hamad Medicalits history only10 open or runningphase 3since Nov 24, 2020Nov 24, 2020none ahead

Also a collaborator on its studies: Tigermed Consulting and CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Swedish Orphan Biovitrum only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2016First study: phase 2 study in GoutFirst studyNCT03002974 · 165 enrolled · United States
  2. Aug 25, 2017Phase 3 study in Still's Disease, Adult-OnsetNCT03265132 · 13 enrolled · United States, Canada
  3. Mar 25, 2020Phase 3 study in SARS-CoV-2NCT04324021 · 16 enrolled · United States, Italy
  4. Nov 22, 2022Phase 3 study in Arthritis, JuvenileNCT05814159 · 15 enrolled · Japan
  5. Oct 8, 2024Phase 4 study in Familial Mediterranean FeverNCT06666335
  6. Jun 24, 2026Phase 4 study in Arthritis, JuvenileNCT07706868

TargetBeta

IL1A →read by rule
“A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist ”NCIt, by rule

Other programs on IL1A

ProgramCompanyFurthest phaseStudies
lutikizumabAbbViephase 312
ABBV-1451AbbViephase 11

Studies

All 6 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07706868Arthritis, Juvenile4WithdrawnSep 30, 20280
NCT06666335Familial Mediterranean Fever4WithdrawnAug 30, 20270
NCT05814159Arthritis, Juvenile · Japan3Active, not recruitingDec 10, 202515
NCT04324021SARS-CoV-2 · United States, Italy3TerminatedNov 13, 202016
NCT03265132Still's Disease, Adult-Onset · United States, Canada3TerminatedFeb 13, 201913
NCT03002974Gout · United States2CompletedJun 2018165

How it is read

Names in the registry

  • “Anakinra”, 5 entries
  • “Anakinra (Kineret®)”, 2 entries
  • “anakinra”, 2 entries
  • “AMG 719”, 2 entries
  • “Anakinra 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.